Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

462 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings.
Goldenberg NA, Abshire T, Blatchford PJ, Fenton LZ, Halperin JL, Hiatt WR, Kessler CM, Kittelson JM, Manco-Johnson MJ, Spyropoulos AC, Steg PG, Stence NV, Turpie AG, Schulman S; Kids-DOTT Trial Investigators. Goldenberg NA, et al. Among authors: halperin jl. J Thromb Haemost. 2015 Sep;13(9):1597-605. doi: 10.1111/jth.13038. Epub 2015 Aug 11. J Thromb Haemost. 2015. PMID: 26118944 Free PMC article. Clinical Trial.
Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm?
Spyropoulos AC, Goldenberg NA, Kessler CM, Kittelson J, Schulman S, Turpie AG, Cutler NR, Hiatt WR, Halperin JL; Antithrombotic Trials Leadership and Steering Group (ATLAS). Spyropoulos AC, et al. Among authors: halperin jl. J Thromb Haemost. 2012 Dec;10(12):2621-4. doi: 10.1111/jth.12005. J Thromb Haemost. 2012. PMID: 23006126 Free article. No abstract available.
Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach.
Kittelson JM, Spyropoulos AC, Halperin JL, Kessler CM, Schulman S, Steg G, Turpie AG, Cutler NR, Hiatt WR, Goldenberg NA; Antithrombotic Trials Leadership and Steering (ATLAS) Group. Kittelson JM, et al. Among authors: halperin jl. J Thromb Haemost. 2013 Aug;11(8):1443-8. doi: 10.1111/jth.12324. J Thromb Haemost. 2013. PMID: 23773172 Free PMC article. Review.
A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2).
Lip GY, Halperin JL, Petersen P, Rodgers GM, Pall D, Renfurm RW. Lip GY, et al. Among authors: halperin jl. J Thromb Haemost. 2015 Aug;13(8):1405-13. doi: 10.1111/jth.13025. Epub 2015 Jul 15. J Thromb Haemost. 2015. PMID: 26052866 Free article. Clinical Trial.
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, Peters G, Spiro T, Steg PG, Suh EY, Weitz JI. Raskob GE, et al. Thromb Haemost. 2016 Jun 2;115(6):1240-8. doi: 10.1160/TH15-09-0756. Epub 2016 Feb 4. Thromb Haemost. 2016. PMID: 26842902 Free article. Clinical Trial.
Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation.
Kittelson JM, Steg PG, Halperin JL, Goldenberg NA, Schulman S, Spyropoulos AC, Kessler CM, Turpie AG, Cutler NR, Hiatt WR; Antithrombotic Trials Leadership and Steering (ATLAS) Group. Kittelson JM, et al. Among authors: halperin jl. Thromb Haemost. 2016 Aug 30;116(3):544-53. doi: 10.1160/TH15-12-1000. Epub 2016 Jun 23. Thromb Haemost. 2016. PMID: 27346176
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators. Spyropoulos AC, et al. Among authors: halperin jl. N Engl J Med. 2018 Sep 20;379(12):1118-1127. doi: 10.1056/NEJMoa1805090. Epub 2018 Aug 26. N Engl J Med. 2018. PMID: 30145946 Free article. Clinical Trial.
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Lu W, Spiro TE, Barnathan ES, Raskob GE. Spyropoulos AC, et al. Among authors: halperin jl. J Am Coll Cardiol. 2020 Jun 30;75(25):3140-3147. doi: 10.1016/j.jacc.2020.04.071. J Am Coll Cardiol. 2020. PMID: 32586587 Free PMC article. Clinical Trial.
Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial.
Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Sharifova G, Cohen M, Lund JM, Mignatti A, Gianos E, Tafur A, Lewis PA, Cohoon K, Kittelson JM, Lesser ML, Sison CP, Rahman H, Ochani K, Hiatt WR, Dale RA, Anderson VE, Bonaca M, Halperin JL, Weitz JI, Spyropoulos AC. Goldin M, et al. Among authors: halperin jl. Thromb Haemost. 2021 Dec;121(12):1684-1695. doi: 10.1055/a-1475-2351. Epub 2021 May 28. Thromb Haemost. 2021. PMID: 33823560
462 results